ChimeriVax-Dengue

Drug Overview

ChimeriVax-Dengue (Sanofi Pasteur) is a tetravalent vaccine comprised of four monovalent, chimeric LAVs. The vaccine is currently in preregistration in six unspecified Latin American and Asia Pacific markets, and Sanofi Pasteur is expected to launch the vaccine in early adopter markets from the end of 2015 (DVI, 2013; Sanofi Pasteur, 2015a). Datamonitor Healthcare expects that Sanofi Pasteur will primarily target Brazil, Colombia, Honduras, India, Indonesia, Malaysia, Mexico, Puerto Rico, Philippines, Singapore, Thailand, and Vietnam, based on the sites included in ChimeriVax-Dengue’s pivotal Phase III trials and the fact that the burden of dengue disease is highest in these markets.

Analyst Outlook

Following its anticipated launch from Q4 2015, Sanofi Pasteur’s ChimeriVax-Dengue (tetravalent liveattenuated
chimeric vaccine) will address a major unmet need as the first-to-market dengue fever
vaccine. Driven by the increasing incidence and economic burden of dengue fever in Asia Pacific and
Latin American regions, and by ChimeriVax-Dengue’s strong protective efficacy against severe dengue
disease, Datamonitor Healthcare expects that early adopter markets will move quickly to incorporate
the vaccine into routine immunization schedules. Although payers in low- and middle-income markets
are expected to reimburse ChimeriVax-Dengue at a relatively low price per dose compared to other
vaccines, Sanofi Pasteur stands to benefit greatly as an anticipated increase in the availability of
doses allows a gradual expansion of immunization programs to include one-off catch-up vaccinations
for adolescents and young adults. However, from H2 2019, ChimeriVax-Dengue faces the threat of
obsolescence from rival live-attenuated vaccines (LAVs) and alternative vaccine approaches, which
have the potential to provide superior protection against serotype 2 infections and/or shorter dosing
schedules.